Brief: Lytix Biopharma Q3 Loss For Period Widens To NOK 18.2 Million
Nov 9 (Reuters) - Lytix Biopharma AS LYTIX.OL :
* Q3 TOTAL OPERATING INCOME NOK 4.3 MILLION VERSUS NOK 3.0
MILLION
YEAR AGO
* Q3 LOSS FOR PERIOD NOK 18.2 MILLION VERSUS LOSS NOK 11.1
MILLION
YEAR AGO
Source text for Eikon: ID:nObiftmrKa
Further company coverage: LYTIX.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program